First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

Eric Helmer,Mark Watling,Emma Jones,Dominique Tytgat,Mark Jones,Rodger Allen,Andrew Payne,Annelize Koch,Eugene Healy

First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

2017

Eric Helmer
Mark Watling
Emma Jones
Dominique Tytgat
Mark Jones
Rodger Allen
Andrew Payne
Annelize Koch
Eugene Healy

Purpose PI3Ks are potential therapeutic targets in immune-inflammatory diseases. These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans.

Keywords:

Small molecule
Diabetes mellitus
Anesthesia
Pharmacodynamics
Immune system
Medicine
Seletalisib
Bioavailability
Pharmacology
Tolerability
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations